[
  {
    "ts": null,
    "headline": "3 Potential Mid-Cap Biotech Buyout Targets In 2026",
    "summary": "Read about the 3 potential midcap biotech stocks primed for acquisition in 2026 amid rising M&A activity.",
    "url": "https://finnhub.io/api/news?id=b80d4fcf43cf5eb72305a5e2e1136fb788574bf0ee61d19151f95b9916aa996f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764786177,
      "headline": "3 Potential Mid-Cap Biotech Buyout Targets In 2026",
      "id": 137674630,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2190546601/image_2190546601.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Read about the 3 potential midcap biotech stocks primed for acquisition in 2026 amid rising M&A activity.",
      "url": "https://finnhub.io/api/news?id=b80d4fcf43cf5eb72305a5e2e1136fb788574bf0ee61d19151f95b9916aa996f"
    }
  },
  {
    "ts": null,
    "headline": "Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight",
    "summary": "The sickle cell disease market is anticipated to grow by 2034, driven by advances in disease mechanisms that have yielded new diagnostic and therapeutic approaches, opening the way to more drug development. In addition, the increasing prevalence and the launch of emerging therapies, such as inclacumab (Pfizer), etavopivat (Novo Nordisk), mitapivat (Agios Pharmaceuticals), osivelotor (Pfizer), and others, will also contribute to the growing market size during the forecast period.New York, USA, De",
    "url": "https://finnhub.io/api/news?id=3ffa9512a2b57f692f081f439b252360900b2fc871dc93eb54c4d9134c6e762d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764784800,
      "headline": "Sickle Cell Disease Market is Predicted to Exhibit Remarkable Growth at a CAGR of 22.1% During the Forecast Period (2025–2034) Across 6MM, Owing to the Increasing Prevalence, Awareness, and Advancements in Gene Therapies | DelveInsight",
      "id": 137677987,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "The sickle cell disease market is anticipated to grow by 2034, driven by advances in disease mechanisms that have yielded new diagnostic and therapeutic approaches, opening the way to more drug development. In addition, the increasing prevalence and the launch of emerging therapies, such as inclacumab (Pfizer), etavopivat (Novo Nordisk), mitapivat (Agios Pharmaceuticals), osivelotor (Pfizer), and others, will also contribute to the growing market size during the forecast period.New York, USA, De",
      "url": "https://finnhub.io/api/news?id=3ffa9512a2b57f692f081f439b252360900b2fc871dc93eb54c4d9134c6e762d"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=47e153b3c8d5565184a24e370ec55fdad31c7fdf7e2cd5473f554d97c891b1f7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764779760,
      "headline": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "id": 137683987,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Pfizer Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=47e153b3c8d5565184a24e370ec55fdad31c7fdf7e2cd5473f554d97c891b1f7"
    }
  },
  {
    "ts": null,
    "headline": "Citigroup Reiterates Pfizer (PFE) Neutral Recommendation",
    "summary": "Citigroup Reiterates Pfizer (PFE) Neutral Recommendation",
    "url": "https://finnhub.io/api/news?id=59708ff7a6f6b5c799dd290ef8c276e1e9128e3f5d481bdb9b8375317f245b61",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764720325,
      "headline": "Citigroup Reiterates Pfizer (PFE) Neutral Recommendation",
      "id": 137665453,
      "image": "",
      "related": "PFE",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=59708ff7a6f6b5c799dd290ef8c276e1e9128e3f5d481bdb9b8375317f245b61"
    }
  }
]